Associated Genetic Biomarkers
Signal transducer and activator of transcription 2 (STAT2) is a gene that encodes a member of the STAT protein family that functions as a transcription activator when translocated to the nucleus of a cell. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as cervical cancer, endometrial cancer, and intestinal cancer.
STAT2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT2 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT2 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT2 Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT2 as an inclusion criteria .
Significance of STAT2 in Diseases
Malignant Solid Tumor +
STAT2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.